

CAPITOLHEALTH

2021 RESULTS Year Ended 30 June 2021

Justin Walter – Chief Executive Officer & Managing Director Craig Bremner – Chief Financial Officer



TABLE OF CONTENTS

- 01. Highlights
- 02. Financials
- 03. Growth
- 04. Appendix

For further information please contact Craig Bremner | CFO | +61 (0) 438 820 112 | <u>c.bremner@capitolhealth.com.au</u>





FY21 RESULTS SUMMARY





2021 HIGHLIGHTS

Key Achievements and Highlights

- Revenue from operations up 15.7% on pcp to \$178.0m
- Operating costs* up 10.7% on pcp to \$130.0m
- Operating EBITDA* increased by 32.1% on pcp to \$48.0m
- Statutory NPAT up 1,005.6% on pcp to \$12.0m
- Strategic plan implementation driving operating margin expansion
- Operating Margin of 27.0% up from 23.6% pcp
- Operating Margin ex JobKeeper 23.7% up from 20.7% pcp
- Management focus on sustained market share growth gaining traction
- COVID-19 impacts successfully managed to date while continuing to provide
 essential services to referrers and patients
- All clinical roles maintained through the pandemic lockdowns whilst experiencing reduced demand for services
- Direct Radiology acquisition integrated and delivering on expectations
- New Camberwell, Morley and Mile End sites opened
- Final dividend for FY21 declared at 0.5 cents per share fully franked



* Operating excludes Transaction & Restructure Costs, Unrealised Foreign Exchange Gain/(Loss), Impairment of Financial Asset and Financial Liabilities movement in fair value.




2021 HIGHLIGHTS

Delivered on Strategic plan:

- · Organic growth initiatives driving results
- Margin expanded and consolidated
- Referrer relationships enhanced with CRM implemented
- · Patient experience now continually measured via net promoter scores and surveys
- E-referral implemented nationally
- · Annual staff survey and employee value proposition in place
- Optimised staffing to clinic demand
- New national telephony system rollout underway to improve patient / referrer experience
- Consolidated multiple data centres to a single outsourced solution
- Enhanced cyber-security protections across network
- Efficiently managed asset utilisation and allocations across network
- Further consolidation of clinics into larger nearby sites
- Corporate risk framework overhauled.




INDUSTRY GROWTH RETURNING



- High rolling growth rates between March to June 2021 are due to the most COVID impacted months (March – April 2020) falling into previous corresponding period
- Rolling 12 month growth rates for DI Revenues and Services experienced a steep decline during the nationwide lockdown between March and May 2020 and was further impacted by the second Victorian lockdown that commenced in July 2020
- DI revenues are increasing due to additional MRI licenses in FY20 (prior to Covid-19) and MBS indexation of certain items from July 2020


¹ – Data included in each graph is inclusive of only the states in which Capitol Health operates in (VIC, TAS, WA, SA) Source: Medicare Australia Statistics - http://medicarestatistics.humanservices.gov.au/statistics/mbs_group.jsp



- GP attendances have returned to long-term averages prior to COVID-19 of above 6% assisted by telehealth services
- Demand for DI services in Victoria has also bounced back but true growth rate is affected by the most COVID impacted months (March – April 2020) falling into previous corresponding period calculations



ROBUST & RELIABLE SOURCE OF REVENUE



Total Revenue Mix (\$m)

- Capitol's community clinic sites and bulk billing revenue stream remains a robust and reliable income source
- Out of pocket revenue increasing at a higher rate due to subtle changes in the service mix
- Full year of Fowler Simmons (acquired in March 2020) and the acquisition of Direct Radiology in February 2021 has further increased the ratio of out of pocket (OOP) revenue due to specialist diagnostic services


| Rev Mix % | FY18 | FY19 | FY20 | FY21 |
|-----------|------|------|------|------|
| Bulk Bill | 81% | 79% | 78% | 76% |
| Other | 19% | 21% | 22% | 24% |



FY 2021 – OPERATING RESULTS

| Operating EBITDA reconciliation \$000 | FY21 | FY20 | Change | % Change |
|---|-----------|----------|----------|----------|
| Revenue | 177,996 | 153,791 | 24,205 | 15.7% |
| Wages, Contractor Costs, Salaries | (102,009) | (91,729) | (10,280) | (11.2%) |
| Other Operating Costs | (27,964) | (25,704) | (2,260) | (8.8%) |
| Operating EBITDA | 48,023 | 36,358 | 11,665 | 32.1% |
| Operating EBITDA Margin | 27.0% | 23.6% | 3.3% | 14.1% |
| Revaluation/(impairment) of financial assets | (734) | (1,619) | 885 | 54.7% |
| Unrealised Foreign Exchange Gain/(loss) | (1,882) | 343 | (2,225) | (648.5%) |
| Transaction and restructure costs | (1,266) | (3,053) | 1,786 | 58.5% |
| Movement of other financial liabilities | 74 | - | 74 | n/m |
| Profit before Finance Costs, Income Tax, Depreciation and Amortisation | 44.215 | 32.029 | 12.186 | 38.1% |

- Revenue of \$178.0m is up \$24.2m or 15.7% over pcp
- Wages, Contractor Costs and Salaries increased by \$10.3m or 11.2% on pcp
- Other Operating Costs increased by \$2.3m or 8.8% on pcp
- Operating margin expansion due to utilisation of higher end modalities, systematic cost out and operational reviews
- Operating EBITDA of \$48.0m, an increase of \$11.7m or 32.1% on pcp
- Operating EBITDA margin increases to 27.0% (ex JobKeeper 23.7%), up from 23.6% pcp
- Unrealised Foreign Exchange Loss relates to the FX rate movement of Enlitic investment (AUD:USD)
- · Revaluation/Impairment to the fair value movement of the Enlitic investment



CAPITOLHEALTH

FY 2021 – CASH FLOW

| Key Cash Measures \$000 | FY21 | FY20 | % Change |
|--------------------------|---------|---------|----------|
| Net Cash from Operations | 40,891 | 35,009 | 16.8% |
| Maintenance CAPEX | (5,330) | (6,151) | (13.4%) |
| Lease payments | (9,701) | (8,283) | 17.1% |
| Free Cash Flow | 25,861 | 20,575 | 25.7% |
| FCF/Operating EBITDA | 53.9% | 56.6% | |

- Generated free cash flow of \$25.9m up 25.7% on pcp
- Free cash flow conversion on operating EBITDA of 53.9% down slightly on pcp of 56.6%
- Maintenance CAPEX investment down slightly due to COVID-19 constraints and improved asset allocation methodologies





CAPITAL MANAGEMENT



- \$110.8m of unused Facilities
- Net debt \$11.1m (excl. AASB 16 Leases)
- Gearing at 0.2 times operating EBITDA provides significant headroom for growth, particularly acquisitions
- Making considered capital management decisions based on the best use of capital and shareholder returns, with reference to:
- Company strategy
- Market outlook
- Opportunity cost of a range of growth alternatives
- Return on investment
- Positive EPS Impact

- No share buy-back in FY21 as the business identifies greater returns for capital
- The company refreshed its buyback capacity in August 2019, allowing a further 76.8m shares to be acquired
- The company continues its commitment to buying back shares when the share price is not reflective of value

- Declared a final dividend for FY21 of 0.5 cents per share
- The company continues its commitment to a sustainable fully franked dividend

FY 2021- CAPEX INVESTMENT

| Capital Expenditure | \$000 | FY21 | FY20 |
|-----------------------------|-------|----------|----------|
| Maintenance | | 5,330 | 6,151 |
| Growth | | 2,312 | 6,014 |
| Total | | 7,642 | 12,165 |
| | | | |
| Depreciation & Amortisation | | (21,396) | (26,025) |


- Maintenance CAPEX investment approach has been reviewed to ensure that Capitol is optimising current asset utilisation, reflecting revenue growth and required replacement levels to avoid capital sensitivity impacts and unnecessary capex spend
- Expansion/growth CAPEX slightly lower than anticipated due to COVID -19 constraints
- Camberwell site opened October 20
- Morley and Mile End sites opened in February 21 and March 21 respectively
- Depreciation & Amortisation was at a higher level in FY20 due to accelerated depreciation and revaluation of older machines and leasehold assets







4 ENGINES OF GROWTH



- During FY20 we undertook a review of the cost base and where we could improve efficiencies.
 This approach continued to deliver in FY21
- We successfully matched patient demand to our resourcing
- In FY21 we focused on market share and the 'go to' market strategy for organic growth

We continue to review and optimise our network of clinics.

There are three prongs to this approach:

- Open Greenfield Clinics
- Brownfield redevelopment and upgrading of modalities
- Clinic portfolio review of profitability

- Location that complements our network
- Alignment with our Company Vision, Values and Strategy
- Where clinic investment will drive organic growth
- To obtain access to people and systems
- Where synergies have been identified
- Pricing makes sense and will deliver value to shareholders.


- New employee engagement software
- Communications and data centre strategy
- Datawarehouse created with new
 BI Tool
- Referrer interface software and telehealth functionality
- Unlisted investment in Enlitic a leading AI software developer in Radiology



PROGRESS FOR FUTURE ORGANIC GROWTH

Key Growth Drivers

- Market demand for services recovering, driven by fundamentals of macro drivers, although Covid-19 risks remain
- Strong bounce back following lockdowns, demonstrates the resilience of demand for our diagnostic imaging services
- Focus continues on the existing business and the development of a rolling bolt on acquisition and Greenfield/Brownfield pipeline to continue momentum and growth
- Building on our commitment to patients, staff activity will more closely align with patient demand – measured in real-time through investment in new systems
- Regular 'cost-to-serve' reviews improving efficiencies at a day-to-day level
- Our portfolio approach to clinic review will ensure appropriate community coverage and diagnostic modalities
- Progressing new services within network eg. Cardiac Imaging, Womens Health.
- Medicare DI indexation July 2021 approx 0.9% average across 60% of CAJ item codes
- · Data driven decision making with BI, CRM, operational analysis






PROGRESS FOR FUTURE ORGANIC GROWTH

Outlook

- Standard operating model implementation to catalyse scalability
- Focus on continuing to deliver both revenue and operating EBITDA organic growth
- Brand rationalization and refresh
- Investment in the front end of our business in operations systems and communications optimization
- Continuing to improve the 'cost-to-serve' of the business
- Carry a strong balance sheet during the period of uncertainty due to the Covid-19 pandemic while investing in well defined growth opportunities
- · Position to continue to pursue value-creative acquisitions







04. APPENDIX



CAPITOLHEALTH

THE CAPITOL HEALTH BUSINESS



LIMITED

FY 2021 – CASH FLOW


| Cash Flow Summary | \$000 | FY21 | FY20 | % Change |
|--|-------|-----------|-----------|----------|
| Cash receipts | | 178,092 | 155,044 | |
| Cash payments | | (126,380) | (117,456) | |
| Net Interest | | (3,377) | (3,837) | |
| Income tax paid | | (7,444) | 1,258 | |
| Net Cash from operations | | 40,891 | 35,009 | 16.8% |
| Cash flows from Investing Activities | | | | |
| Payments of Capex | | (7,642) | (12,165) | |
| Payments for Business Acquisitions | | (13,702) | (20,680) | |
| Payments for Investments | | | | |
| Net Cash from Investing Activities | | (21,344) | (32,845) | 35.0% |
| Cash flows from Financing Activities | | | | |
| Proceeds from Conversion of Share Options | | 393 | - | |
| Payment of Dividends | | (14,135) | (3,842) | |
| Payments of dividends to non-controlling interests | 6 | (118) | - | |
| Net proceeds on Issue/(Buy Back) Share Capital | | - | 38,144 | |
| Proceeds of Borrowings | | 12,000 | (21,750) | |
| Payments for leasing arrangements | | (9,701) | (8,283) | |
| Net Cash from Financing Activities | | (11,561) | 4,269 | (370.8%) |
| Net increase/(decrease) in Cash and equivaler | its | 7,986 | 6,433 | |
| Cash at Beginning | | 13,763 | 7,330 | |
| Cash at End | | 21,749 | 13,763 | 58.0% |





FY 2021 – STRONG BALANCE SHEET

| | A 1000 | 00.1 | 00 L 0000 |
|--|---------------|--------------|--------------|
| Balance Sheet Summary Current Assets | \$'000 | 30 June 2021 | 30 June 2020 |
| | | 04 740 | 40 700 |
| Cash and Cash Equivalents Trade and Other Receivables | | 21,749 | 13,763 |
| | | 5,582 | 5,493 |
| Other Financial Assets | | 169 | 277 |
| Other Assets | | 787 | 767 |
| Total Current Assets | | 28,287 | 20,300 |
| Non-Current Assets | | | |
| Plant & Equipment | | 41,075 | 40,820 |
| Right-of-Use Asset | | 59,011 | 54,729 |
| Intangible Assets | | 126,035 | 117,949 |
| Other Financial Assets NC | | 19,522 | 22,138 |
| Other Receivables | | 180 | 630 |
| Deferred Tax Assets | | 5,650 | 5,741 |
| Total Non-Current Assets | | 251,473 | 242,007 |
| Total Assets | | 279,760 | 262,307 |
| Current Liabilities | | | |
| Trade and Other Payables | | 13,606 | 16,967 |
| Lease Liability | | 9,782 | 9,640 |
| Employee Benefit Liabilty | | 12,239 | 10,828 |
| Income Tax Liability | | 1,973 | 2,751 |
| Total Current Liabilities | | 37,600 | 40,186 |
| Non-Current Liabilities | | | |
| Loans and Borrowings NC | | 29,000 | 17,000 |
| Lease Liability | | 55,284 | 52,702 |
| Other financial liability | | 5,081 | 3,698 |
| Provisions | | 2,455 | 1,340 |
| Employee Benefit Liabilty NC | | 781 | 852 |
| Deferred Tax Liabilities | | 3,531 | 2,490 |
| Total Non-Current Liabilities | | 96,132 | 78,082 |
| Total Liabilities | | 133,732 | 118,268 |
| Net Assets | | 146,028 | 144,039 |



CAPITOLHEALTH

CAPITOL HEALTH

CAPITOL HEALTH VISION

To be the diagnostic imaging specialists of choice, serving communities with compassion, integrity and precision

OUR VALUES



Patient Centered

We create positive patient experiences. We listen with respect, inform with empathy and involve patients in their care



One Team

Our people are our best asset.

Our outcomes are better when

we work together. We treat

each other with respect and

nurture a culture of recognition,

empathy and inclusion

Integrity

We are open and honest. We take pride in the way we work. Our patients and partners trust us because we are accountable and reliable Together we pursue excellence – in outcomes and experience for our patients, referrers and community. We utilise the best technology to deliver timely, precise results

Excellence

Community Focused

We are more than a network; we are a community. We create meaningful connections with our patients, referrers and colleagues built on trust, support and shared goals



THE PILLARS OF OUR BUSINESS

| Operational Excellence | Destination Employer | Next-generation Technology | First-choice Provider | Values-based Communications |
|--|--|---|---|--|
| Standardised operating model as platform for organic growth Value creation through post-acquisition integration Performance management through business intelligence and analytics | Employee Value Proposition Clear performance & reward mechanisms Focus on professional development Values driven people processes | Highly secure and effective technology model Holistic approach to technology encompassing clinical outcomes, operational efficiency and patient experience | Differentiate customer and marketing plan Focus on and resourcing referrer relationship management including CRM implementation Patient experience management | Coherent stakeholder communications strategy Focus on developing industry and government relationships Industry thought leadership program |

CAPITOL HEALTH STRATEGIC PILLARS



LIMITED

DISCLAIMER

This presentation is the property of Capitol Health Limited (Capitol). This presentation is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security and neither this presentation nor anything contained in it shall form the basis of any contract or commitment.

This presentation does not constitute an offer or invitation in any jurisdiction anywhere, or to any person to whom, such an offer would be unlawful. This presentation is not intended as an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the United States or to any person to whom it is unlawful to make such an offer or solicitation. The securities that may be included in any offering have not been, and will not be registered under the US Securities Act.

Reliance should not be placed on the information or opinions contained in this presentation. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Any decision to purchase or subscribe for securities in Capitol must be made solely on the basis of the information contained in the in the public domain and if necessary, after seeking appropriate financial advice.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, Capitol and its affiliates and related bodies corporate, and their respective officers, directors, employees and agents disclaim any liability (including, without limitation, any liability arising from fault or negligence) for any loss arising from any use of this presentation (or its content) or otherwise arising in connection with it.

Capitol's forward-looking statements, intentions, forecasts, prospects, returns, expectations, statements in relation to future matters or other forward-looking statement contained in this presentation may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. They are based on a number of estimates, assumptions that are subject to business, scientific, economic and competitive uncertainties and contingencies, with respect to future business decisions, which are subject to change and, in many cases, are outside the control of Capitol and its directors. Neither Capitol nor its directors give any assurance that the forecast performance in the forecasts or any forward-looking statement contained in this presentation will be achieved.

